Ypeginterferon alfa-2b

DRUG5 trials

Sponsors

Xiamen Amoytop Biotech Co., Ltd.

Conditions

Chronic Hepatitis BChronic Hepatitis C

Phase 2

Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C

CompletedNCT01140997

Xiamen Amoytop Biotech Co., Ltd.Chronic Hepatitis C

Start: 2010-07-31End: 2012-03-31Updated: 2013-02-04

Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

CompletedNCT01143662

Xiamen Amoytop Biotech Co., Ltd.Chronic Hepatitis B

Start: 2010-07-31End: 2012-04-30Updated: 2013-02-04

A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B

CompletedNCT02332473

Xiamen Amoytop Biotech Co., Ltd.Chronic Hepatitis B

Start: 2014-06-30End: 2016-08-31Updated: 2017-01-25

Phase 3

Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients

CompletedNCT01581398

Xiamen Amoytop Biotech Co., Ltd.Chronic Hepatitis C

Start: 2012-04-30End: 2014-06-30Updated: 2014-10-07

Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

CompletedNCT01760122

Xiamen Amoytop Biotech Co., Ltd.Chronic Hepatitis B

Start: 2013-03-31End: 2015-08-31Updated: 2015-08-31

Related Papers

Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection

BMC Gastroenterology2014-03-1311 citations